IBS to Expand Pilot Production of Pre-filled Syringes to One Million Units

Integrated BioSciences, Inc. (IBS) announces that its parent company, Unilife Medical Solutions, has signed an exclusive license agreement with sanofi-aventis, one of the world’s leading pharmaceutical companies, for the Unilife Ready-to-Fill Syringe (RTFS).  In this agreement, sanofi-aventis retains exclusive rights to the RTFS for a period of five years in exchange for a licensing fee of $16.4 million. IBS began pilot production of the pre-filled syringes earlier this year at its Lewisberry facility and expects to expand pilot production to 1 million units with annual volumes potentially expected to exceed 400 million units at full production.